Reply  by Thomas, James H.
1122 Letters to the Editors 
Regarding "The clinical course of asymptomatic 
mesenteric arterial stenosis" 
To the Editors: 
In the recently published article by James H. Thomas et 
al (J Vasc Surg 1998;27:840-4), the authors concluded that 
prophylactic mesenteric artery reconstruction is reasonable 
in patients with asymptomatic severe stenosis/occlusion in 
all 3 visceral arteries. This is on the basis of the observation 
that in the subgroup of 15 patients who each had 3 vessels 
with severe visceral disease, chronic mesenteric angina 
developed in 3 patients and 1 patient died from extensive 
necrosis of the bowel during a mean follow-up period of2.6 
years. By contrast, none of the remaining 45 patients in this 
study with significant mesenteric artery stenosis, celiac 
artery stenosis, or 2-vessel visceral artery disease in any 
combination experienced symptoms of mesenteric ischemia. 
The primary outcome measure to be considered before 
a decision is made for prophylactic invasive treatment in 
patients who are asymptomatic should be the incidence 
rate of acute mesenteric ischemia. There is a general agree-
ment that this complication is associated with a high mor-
tality rate.l,2 There was only 1 patient in this subgroup of 
15 patients who died from intestinal infarction caused by 
acute intestinal ischemia, which is an incidence rate of 6%. 
The benefit of prophylactic surgery should be balanced 
against the operative risk, which has been reported to be 
between 5% and 17%,3 and the life expectancy, which, as 
the authors have observed, is reduced. In fact, this study 
has shown that most of the patients in this series (15/72) 
died from cardiovascular causes. Thus, significant mesen-
teric artery stenosis is a marker of extensive and severe car-
diacdisease. Patients should be screened at presentation for 
accompanying heart disease, and this should be treated on 
its merits. The rationalism has been similar for the selection 
criteria for carotid endarterectomy in patients with asymp-
tomatic carotid artery stenosis. The primary outcome mea-
sure was the incidence rate of stroke and not the incidence 
rate of transient ischemic attacks.4 
In conclusion, I believe that the case for prophylactic 
mesenteric artery reconstruction in patients with asympto-
matic severe 3-vessel visceral artery disease has not been 
conclusively proven and merits further investigation. 
Geor;ge Geroulakos, MD, PHD 
Department of Surgery 
Chacing Cross Hospital 
London, United Kingdom 
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Reply 
In reviewing the manuscript entitled "The clinical 
course of asymptomatic mesenteric arterial stenosis," Dr 
Geroulakos has concluded that the case for prophylactic 
mesenteric arterial reconstruction in patients with asymp-
tomatic severe 3-vessel visceral artery disease has not been 
proven conclusively and merits further investigation. Dr 
Geroulakos states that the primary outcome measure to be 
considered in patients who are asymptomatic, before a 
decision is to be made for prophylactic invasive treatment, 
should be the incidence rate of acute mesenteric ischemia. 
He notes that only 1 patient in a sub-group of 15 patients 
with 3-vessel mesenteric disease died from intestinal 
infarction caused by acute intestinal ischemia, which is an 
incidence rate of 6%. He also notes that most of the 
patients die of cardiovascular causes. We are in total agree-
ment with Dr Geroulakos' observations, but we differ 
with his conclusions. It would be optimal if all patients in 
whom intestinal infarction developed initially had clinical 
symptoms of chronic mesenteric ischemia. This is clearly 
not the case, and acute mesenteric ischemia often develops 
rapidly in those patients with chronic mesenteric ischemia. 
In our study, the patients were followed closely and, as a 
consequence, any symptoms suggestive of chronic mesen-
teric ischemia were evaluated carefully and immediately. 
Clearly, this may not be the situation in the usual clinical 
setting, but rather the vascular surgeon is often in a situa-
tion where he or she may be dependent on patients' 
reports of their symptoms. In an artificial clinical situation, 
such as this study, this variable was controlled and, as indi-
cated above, all patients were monitored closely. Although 
the recommendation that patients with 3-vessel disease be 
considered for prophylactic mesenteric reconstruction is 
on the basis of small numbers, we remain convinced that 
this is the optimum approach to this difficult problem. 
James H. Thomas, MD 
University of Kansas Medical Center 
Section of Vascular Surgery 
Kansas City, Kan 
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